Whether it’s allergies, a sinus infection or runny nose, many people turn to nasal sprays for quick relief. Now, there’s ...

加利福尼亚州圣地亚哥 - 根据最近向美国证券交易委员会提交的8-K文件，专门从事药物制剂的制药公司ARS Pharmaceuticals, Inc.已修订了与Renaissance Lakewood, LLC的制造协议。该修订于周一生效，修改了原本于2020年9月9日签订并于2023年7月25日修订的协议条款。

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this ...

ARS Pharmaceuticals Inc (SPRY) stock saw a decline, ending the day at $14.77 which represents a decrease of $-0.09 or -0.61% from the prior close of $14.86. The stock opened at $14.97 and touched a ...

ARS Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) for a1 mg dose of nasal spray neffy, to treat ...

The maker of a homeopathic nasal spray with a history of contamination is refusing to recall its product after the Food and ...

ARS Pharmaceuticals Inc (SPRY) stock saw a modest uptick, ending the day at $14.05 which represents a slight increase of $1.00 or 7.66% from the prior close of $13.05. The stock opened at $13.1 and ...

The submission of the neffy 1 mg sNDA follows the FDA approval of neffy (2 mg) on August 9, 2024, for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 kg ...

Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Tuesday, September 17, 2024, at 9:10 a.m.

SAN DIEGO - ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)已提交一份补充新药申请(sNDA),用于neffy® 1 mg,这是一种针对体重15至30公斤(33-66磅)儿童的无针式肾上腺素治疗,用于I型过敏反应,包括过敏性休克。此次提交是在FDA于2024年8月9日批准用于30公斤或以上患者的neffy 2 mg之后进行的。 该公司报告称,neffy ...

Neffy is a small molecule commercialized by ARS Pharmaceuticals, with a leading Pre-Registration program in Anaphylaxis.

ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...